




Supplementary Figure 1. No significant differences were found in response to systematic therapies in HCC with different viral etiologies. (A) Treatment benefit score for sorafenib in the four groups of HCCs. (B) Treatment benefit score for regorafenib in the four groups of HCCs. (C) Immune Class Score for the four groups of HCCs. (D) Immune cell expression according to DanaHER's gene sets among HBV-HCC subgroups.